Dr. Vered Padler-Karavani

Dep. of Cell Research and Immunology
מח חקר התא ואימונולוגיה סגל אקדמי בכיר
Dr. Vered Padler-Karavani
Phone: 03-6406737
Another phone: 03-6405064
Fax: 03-6422046
Office: Britannia-Porter, 306




Post-doctoral fellow; Glycobiology, University of California-San Diego

2000-2005 Ph.D.; Biochemistry, Tel Aviv University
1997-1999 M.Sc.; Biochemistry (magna cum laude), Tel Aviv University
1994-1997 B.Sc.; Biology (magna cum laude); Tel Aviv University


Academic Appointments:

2013-present Senior Lecturer; Department of Cell Research & Immunology, Tel Aviv University
2010-2012 Assistant Project Scientist; Department of Cellular & Molecular Medicine, University of California-San Diego


Honors & Awards:

2013 AAI Early Career Faculty Travel Grant
2009-2011 Edmond J. Safra-ISEF postdoctoral fellowship
2005, 2007 HSBC-ISEF postdoctoral fellowship (awarded to only 10 outstanding international scholars per year)
2004 The Arie and Keren Shenkar award for excellence in studies and teaching.


Research Interests

Our lab is studying the mechanisms that govern glycan immune recognition and responses in animal models and humans, both in vitro and in vivo. We combine glycobiology, immunology, biotechnology and cancer research, and use cutting edge technologies within these disciplines, including glycan microarray and glyco-nanotechnology.


Current interests include:  Immunological mechanisms of unique anti-carbohydrate antibodies; Glycoimmunology in xenotransplantation, as members of the EU TRANSLINK consorsium; Anti-carbohydrate antibodies in mucosal secretions and sera; Development novel diagnostics and therapeutics to chronic inflammation mediated diseases; Development of bio-nanotechnology tools based on glycan recognition.


Recent Publications


Amon R, Grant OC, Leviatan Ben-Arye S, Makeneni S, Nivedha AK, Marshanski T, Norn C, Yu H, Glushka JN, Fleishman SJ, Chen X, Woods RJ, Padler-Karavani V. (2018). A combined computational-experimental approach to define the structural origin of antibody recognition of sialyl-Tn, a tumor-associated carbohydrate antigen. Sci Rep. 8(1):10786.

Paul A, Padler-Karavani V. (2018). Evolution of sialic acids: Implications in xenotransplant biology. Xenotransplantation. 22:e12424.

Samraj AN, Bertrand KA, Luben R, Khedri Z, Yu H, Nguyen D, Gregg CJ, Diaz SL, Sawyer S, Chen X, Eliassen H, Padler-Karavani V, Wu K, Khaw KT, Willett W, Varki A. (2018). Polyclonal human antibodies against glycans bearing red meat-derived non-human sialic acid N-glycolylneuraminic acid are stable, reproducible, complex and vary between individuals: Total antibody levels are associated with colorectal cancer risk. PLoS One. 13(6):e0197464.

Shanthamurthy CD, Jain P, Yehuda S, Monteiro JT, Leviatan Ben-Arye S, Subramani B, Lepenies B, Padler-Karavani V, Kikkeri R. (2018). ABO Antigens Active Tri- and Disaccharides Microarray to Evaluate C-type Lectin Receptor Binding Preferences. Sci Rep. 8(1):6603.

Lop L, Padler-Karavani V, Cozzi E. (2018). Xenotransplantation: The Way beyond and Ahead toward Clinical Application. J Immunol Res. 6191359.

Gade M, Alex C, Leviatan Ben-Arye S, Monteiro JT, Yehuda S, Lepenies B, Padler-Karavani V, Kikkeri R. (2018). Microarray Analysis of Oligosaccharide-Mediated Multivalent Carbohydrate-Protein Interactions and Their Heterogeneity. Chembiochem. [Epub ahead of print].

Mai HL, Treilhaud M, Ben-Arye SL, Yu H, Perreault H, Ang E, Trébern-Launay K, Laurent J, Malard-Castagnet S, Cesbron A, Nguyen TVH, Brouard S, Rostaing L, Houssel-Debry P, Legendre C, Girerd S, Kessler M, Morelon E, Sicard A, Garrigue V, Karam G, Chen X, Giral M, Padler-Karavani V, Soulillou JP. (2018). Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte Globulin in Recipients of a Kidney Graft After Nonrenal Organ Transplantation. Transplant Direct. 4(4):e357.

Amon R, Ben-Arye SL, Engler L, Yu H, Lim N, Berre LL, Harris KM, Ehlers MR, Gitelman SE, Chen X, Soulillou JP, Padler-Karavani V. (2017). Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy. Oncotarget. 8(68):112236-112244.

Leviatan Ben-Arye S, Yu H, Chen X, Padler-Karavani V. (2017). Profiling Anti-Neu5Gc IgG in Human Sera with a Sialoglycan Microarray Assay. J Vis Exp. (125).

Padler-Karavani V. (2016). Glycan Microarray Reveal the Sweet Side of Cancer Vaccines. Cell Chem Biol. 23(12):1446-1447.

Yadav R, Leviatan Ben-Arye S, Subramani B, Padler-Karavani V, Kikkeri R. (2016). Screening of Neu5Acα(2-6)gal isomer preferences of siglecs with a sialic acid microarray. Org Biomol Chem.14(46):10812-10815.

Reuven EM, Leviatan Ben-Arye S, Marshanski T, Breimer ME, Yu H, Fellah-Hebia I, Roussel JC, Costa C, Galiñanes M, Mañez R, Le Tourneau T, Soulillou JP, Cozzi E, Chen X, Padler-Karavani V. (2016). Characterization of immunogenic Neu5Gc in bioprosthetic heart valves. Xenotransplantation. (5):381-92. 

Langereis MA, Bakkers MJ, Deng L, Padler-Karavani V, Vervoort SJ, Hulswit RJ, van Vliet AL, Gerwig GJ, de Poot SA, Boot W, van Ederen AM, Heesters BA, van der Loos CM, van Kuppeveld FJ, Yu H, Huizinga EG, Chen X, Varki A, Kamerling JP, de Groot RJ. (2015). Complexity and Diversity of the Mammalian Sialome Revealed by Nidovirus Virolectins. Cell Rep. 11(12):1966-78.

Padler-Karavani V. (2014). Aiming at the sweet side of cancer: aberrant glycosylation as possible target for personalized-medicine. Cancer Lett. 352(1):102-12.

Amon R, Reuven EM, Leviatan Ben-Arye S, Padler-Karavani V. (2014). Glycans in immune recognition and response. Carbohydr Res. 389:115-22.

UCSD blog: http://ucsdhealthsciences.tumblr.com/post/77737274933/the-red-queen-effect-writ-small-in-what-amounts Featured on FASEB March 2014 issue; “Scientists Learn How Pathogens Hack Our Immune Systems To Go Undetected”: http://www.eurekalert.org/pub_releases/2014-02/foas-slh022714.php

Padler-Karavani V#, Hurtado-Ziola N#, Chang YC, Sonnenburg JL, Ronaghy A, Yu H, Verhagen A, Nizet V, Chen X, Varki N, Varki A, Angata T. (2014). Rapid evolution of binding specificities and expression patterns of inhibitory CD33-related Siglecs in primates. FASEB J. 28(3):1280-93 (# equally contributed).

Padler-Karavani V. (2014). Aiming at the sweet side of cancer: aberrant glycosylation as possible target for personalized-medicine. Cancer Lett. 28;352(1):102-12.

Scobie L#, Padler-Karavani V#, Le Bas-Bernardet S, Crossan C, Blaha J, Matouskova M, Hector RD, Cozzi E, Vanhove B, Charreau B, Blancho G, Bourdais L, Tallacchini M, Ribes JM, Yu H, Chen X, Kracikova J, Broz L, Hejnar J, Vesely P, Takeuchi Y, Varki A, Soulillou JP. (2013). Long-term IgG response to porcine Neu5Gc antigens without transmission of PERV in burn patients treated with porcine skin xenografts. J Immunol. 191(6):2907-15 (# equally contributed).

Kikkeri R, Padler-Karavani V, Diaz S, Verhagen A, Yu H, Cao H, Langereis MA, De Groot RJ, Chen X, Varki A. (2013). Quantum dot nanometal surface energy transfer based biosensing of sialic acid compositions and linkages in biological samples. Anal Chem. 85(8):3864-70

Padler-Karavani V, Tremoulet AH, Yu H, Chen X, Burns JC, Varki A. (2013).


A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease. PLoS One. 8(3):e58443.

UCSD News release: http://health.ucsd.edu/news/releases/Pages/2012-06-04-infectious-disease-shaped-human-origins.aspx

Wang X, Mitra N, Secundino I, Banda K, Cruz P, Padler-Karavani V, Verhagen A, Reid C, Lari M, Rizzi E, Balsamo C, Corti G, De Bellis G, Longo L; NISC Comparative Sequencing Program, Beggs W, Caramelli D, Tishkoff SA, Hayakawa T, Green ED, Mullikin JC, Nizet V, Bui J, Varki A. (2012). Specific inactivation of two immunomodulatory SIGLEC genes during human evolution.Proc Natl Acad Sci 109(25):9935-40.

Padler-Karavani V#, Song X#, Yu H, Hurtado-Ziola N, Huang S, Muthana S, Chokhawala HA, Cheng J, Verhagen A, Langereis MA, Kleene R, Schachner M, de Groot RJ, Lasanajak Y, Matsuda H, Schwab R, Chen X, Smith DF, Cummings RD, Varki A. (2012). Cross-comparison of protein recognition of sialic acid diversity on two novel sialoglycan microarrays. J Biol Chem. 287(27):22593-608 (# equally contributed).

Lu Q#, Padler-Karavani V#, Yu H, Chen X, Wu S-L, Varki A and Hancock WS. (2012) LC-MS analysis of polyclonal human anti-Neu5Gc Xeno-autoantibodies IgG subclass and partial sequence using multi-step IVIG affinity purification and multi-enzymatic digestion. Anal Chem 84(6):2761-8 (# equally contributed).

Padler-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, Muthana S, Chokhawala HA, Cao H, Secrest P, Friedmann-Morvinski D, Singer O, Ghaderi D, Verma IM, Liu YT, Messer K, Chen X, Varki A, Schwab R. (2011) Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res. 71(9):3352-63.

Padler-Karavani V, Varki A. (2011) Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk. Xenotransplantation. 18(1):1-5.

Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S and Varki A. (2010) Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotech. 28(8):863-7.

Taylor RE, Gregg CJ, Padler-Karavani V, Ghaderi D, Yu H, Huang S, Sorensen RU, Chen X, Inostroza J, Nizet V and Varki A. (2010) Novel mechanism for the generation of human xeno-auto-antibodies against the non-human sialic acid N-glycolylneuraminic acid. J Exp Med. 207(8): 1637-1646.

Pham T, Gregg CJ, Karp F, Chow R, Padler-Karavani V, Cao H, Chen X, Witztum JL, Varki NM and Varki A. (2009) Evidence for a Novel Human-specific Xeno-Auto-Antibody Response Against Vascular Endothelium. Blood. 114(25): 5225-35.

Hedlund M, Padler-Karavani V, Varki N, and Varki A. (2008). Evidence for a Human-Specific Mechanism for Diet and Antibody-Mediated Inflammation in Carcinoma Progression. Proc Natl Acad Sci U S A. 105(48): 18936-41.

Padler-Karavani V, Yu H, Cao H, Chokhawala H, Karp F, Varki N, Chen X and Varki A. (2008) Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for disease. Glycobiology. 18(10): 818-30.

Aviezer-Hagai K#, Padler-Karavani V#, Nelson N. (2003) Biochemical support for the V-ATPase rotary mechanism: antibody against HA-tagged Vma7p or Vma16p but not Vma10p inhibits activity. J Exp Biol. 206: 3227-37. (# equally contributed).



Tel Aviv University makes every effort to respect copyright. If you own copyright to the content contained here and / or the use of such content is in your opinion infringing, Contact us as soon as possible >>
Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel
UI/UX Basch_Interactive